134 related articles for article (PubMed ID: 7554780)
21. Factors associated with plasma lipids and lipoproteins in type 1 diabetes mellitus: the EURODIAB IDDM Complications Study.
Idzior-Walus B; Mattock MB; Solnica B; Stevens L; Fuller JH;
Diabet Med; 2001 Oct; 18(10):786-96. PubMed ID: 11678968
[TBL] [Abstract][Full Text] [Related]
22. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM.
Brussaard HE; Gevers Leuven JA; Frölich M; Kluft C; Krans HM
Diabetologia; 1997 Jul; 40(7):843-9. PubMed ID: 9243107
[TBL] [Abstract][Full Text] [Related]
23. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
[TBL] [Abstract][Full Text] [Related]
24. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
[TBL] [Abstract][Full Text] [Related]
25. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism.
Chadarevian R; Bruckert E; Leenhardt L; Giral P; Ankri A; Turpin G
J Clin Endocrinol Metab; 2001 Feb; 86(2):732-7. PubMed ID: 11158038
[TBL] [Abstract][Full Text] [Related]
26. Relationship between endothelial function and fibrinolysis in early hypertension.
Tomiyama H; Kimura Y; Mitsuhashi H; Kinouchi T; Yoshida H; Kushiro T; Doba N
Hypertension; 1998 Jan; 31(1 Pt 2):321-7. PubMed ID: 9453323
[TBL] [Abstract][Full Text] [Related]
27. Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study.
Simpson AJ; Booth NA; Moore NR; Lewis SJ; Gray RS
Acta Diabetol; 1999 Sep; 36(3):155-8. PubMed ID: 10664320
[TBL] [Abstract][Full Text] [Related]
28. Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in Type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study.
Bosnyak Z; Forrest KY; Maser RE; Becker D; Orchard TJ;
Diabet Med; 2003 Feb; 20(2):147-51. PubMed ID: 12581266
[TBL] [Abstract][Full Text] [Related]
29. Inheritance conjointly contributing to fibrinolysis and hyperlipidemia.
Glueck CJ; Glueck HI; Tracy T; Speirs J; Stroop D
Metabolism; 1993 Nov; 42(11):1410-9. PubMed ID: 8231835
[TBL] [Abstract][Full Text] [Related]
30. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
[TBL] [Abstract][Full Text] [Related]
31. Low order correlations of lipoprotein(a) with other blood lipids and with coagulation and fibrinolysis parameters in hypertensive and diabetic patients.
Donders SH; Lustermans FA; van Wersch JW
Blood Coagul Fibrinolysis; 1992 Jun; 3(3):249-56. PubMed ID: 1386533
[TBL] [Abstract][Full Text] [Related]
32. Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes.
Jokl R; Klein RL; Lopes-Virella MF; Colwell JA
Diabetes Care; 1995 Aug; 18(8):1150-5. PubMed ID: 7587850
[TBL] [Abstract][Full Text] [Related]
33. Levels of three hemostatic factors in relation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor.
Crutchley DJ; McPhee GV; Terris MF; Canossa-Terris MA
Arteriosclerosis; 1989; 9(6):934-9. PubMed ID: 2511826
[TBL] [Abstract][Full Text] [Related]
34. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.
Grant PJ
Diabetes Care; 1996 Jan; 19(1):64-6. PubMed ID: 8720537
[TBL] [Abstract][Full Text] [Related]
35. [Selected new atherosclerosis risk factors and markers of fibrinolysis in children and adolescents with obesity, hypertension and diabetes].
Głowińska B; Urban M; Koput A; Galar M
Przegl Lek; 2003; 60(1):12-7. PubMed ID: 12884639
[TBL] [Abstract][Full Text] [Related]
36. Insulin resistance syndrome and fibrinolytic activity: the northern Sweden MONICA study.
Lindahl B; Asplund K; Eliasson M; Evrin P-E
Int J Epidemiol; 1996 Apr; 25(2):291-9. PubMed ID: 9119554
[TBL] [Abstract][Full Text] [Related]
37. Relationship of oxidative stress and fibrinolysis in diabetes mellitus.
Skrha J; Hodinár A; Kvasnicka J; Hilgertová J
Diabet Med; 1996 Sep; 13(9):800-5. PubMed ID: 8891455
[TBL] [Abstract][Full Text] [Related]
38. The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients.
Orem C; Uydu HA; Yilmaz R; Gökçe M; Baykan M; Eminagaoglu S; Orem A
Jpn Heart J; 2004 Nov; 45(6):977-87. PubMed ID: 15655273
[TBL] [Abstract][Full Text] [Related]
39. Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels.
Bröijersen A; Eriksson M; Wiman B; Angelin B; Hjemdahl P
Arterioscler Thromb Vasc Biol; 1996 Apr; 16(4):511-6. PubMed ID: 8624772
[TBL] [Abstract][Full Text] [Related]
40. Plasma Lp(a) and t-PA-PAI-1 complex levels in coronary heart disease.
Süer S; Ulutin T; Sönmez H; Kökoğlu E; Uçişik N; Bayram C; Sultuybek G
Thromb Res; 1996 Jul; 83(1):77-85. PubMed ID: 8837306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
